BNTX vs MRK
BioNTech SE vs Merck & Co. — AI-powered side-by-side comparison
| Metric | BNTX | MRK |
|---|
| AI Score |
66
|
70
|
| Price |
$92.76
|
$130.34
|
| P/E Ratio |
-11.76×
|
103.53×
|
| ROE |
-5.7%
|
34.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
68.9%
|
75.4%
|
| Debt / Equity |
0.02×
|
1.29×
|
| Dividend Yield |
0.0%
|
2.6%
|
| RSI (14) |
54.0
|
64.5
|
| Beta |
1.278
|
0.207
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for BNTX versus MRK.
MRK leads by 4 points.
MRK scores 70/100 (Buy) versus BNTX at 66/100 (Buy).
BNTX Committee View
50% agreement
4 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
MRK Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical